Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114272 | 1.00 | CHRM2 (0.51) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL3853785 | 1.00 | CHRM2 (0.51) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL9265646 | 0.95 | CHRNB2 (0.48) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL9261614 | 0.95 | CHRNB2 (0.48) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL9268819 | 0.93 | CHRNB2 (0.47) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL9257279 | 0.93 | CHRNB2 (0.47) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL9263385 | 0.93 | CHRNB2 (0.47) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Oxalic Acid SCHEMBL8104972 | 0.91 | CHRNB2 (0.44) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| Oxalic Acid SCHEMBL8114514 | 0.91 | CHRNB2 (0.44) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL9265217 | 0.87 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-5516912-A | FROM PROTECTED 2-OXOPYRROLIDINE | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | claimed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| WO-2018114596-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| EP-1943215-A2 | PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Brystol-Myers Squibb Company (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20070249622-A1 | Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases | UNIVERSITE LAVAL | 2007-10-25 | — | — | US | disclosed |
| WO-2007053819-A2 | PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | CHRM2 4720/4885CHRM5 4678/4885CHRM3 4726/4885 |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | DDT, NOTUM, AGPS | CHRM2 1499/4885CHRM5 2488/4885CHRM3 2466/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | CHRM2 4636/4885CHRM5 4537/4885CHRM3 4718/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | CHRM2 186/4885CHRM5 452/4885CHRM3 267/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | CHRM2 2697/4885CHRM5 3871/4885CHRM3 2675/4885 |
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | GLP1R, GPR119, SLC5A2 | CHRM2 99/4885CHRM5 808/4885CHRM3 536/4885 |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | CHRM2 3735/4885CHRM5 3751/4885CHRM3 3213/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | CHRM2 3728/4885CHRM5 3021/4885CHRM3 3882/4885 |
| US-20070249622-A1 | Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases | CHRNA1, NR3C1, CHRNG | CHRM2 51/4885CHRM5 45/4885CHRM3 20/4885 |
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | IGF1R, IGFBP1, IGFBP2 | CHRM2 4487/4885CHRM5 4426/4885CHRM3 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.